Pharma BD Deal Intelligence
Avibactam became a real approved antibiotic, but AstraZeneca exited the whole category to Pfizer within a decade rather than commercialize its own prize.
Full analysis, sources & comparables →AstraZeneca to acquire 100% of Novexel for $350M cash plus up to $75M in milestones, with Forest Laboratories paying half the acquisition cost in return for…
AstraZeneca snaps up antibiotics company Novexel for US$505 million, a Sanofi-Aventis anti-infectives spin-off, to bolster its resistant-infection drug…
Avibactam, originally NXL104, was approved as Avycaz (ceftazidime/avibactam) in 2015 for complicated UTIs and intra-abdominal infections, validating…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
$350M cash + up to $75M milestones + ~$80M cash transfer. Beta-lactamase inhibitor NXL104 (avibactam). Linked Forest co-acquisition: Forest paid AZ ~half. Source: AstraZeneca press, Jones Day, S&P Global.
Avibactam became a real approved antibiotic, but AstraZeneca exited the whole category to Pfizer within a decade rather than commercialize its own prize.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Novexel S.A. (this deal) | 2009 | $505M | 52 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2009 deals · AstraZeneca PLC deals